Principal Financial Group Inc Evolus, Inc. Transaction History

Principal Financial Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$10.66 - $17.48 $29,773 - $48,821	-2,793 Reduced 8.42%	30,381 $492,000
Q2 2024 Jul 29, 2024	SELL	$10.45 - $13.76 $16,834 - $22,167	-1,611 Reduced 4.63%	33,174 $359,000
Q1 2024 Apr 29, 2024	BUY	$9.99 - $14.91 $203,706 - $304,029	20,391 Added 141.66%	34,785 $486,000
Q4 2023 Feb 07, 2024	SELL	$7.6 - $10.53 $1,208 - $1,674	-159 Reduced 1.09%	14,394 $151,000
Q3 2023 Nov 02, 2023	BUY	$7.15 - $10.2 $2,123 - $3,029	297 Added 2.08%	14,553 $133,000
Q2 2023 Aug 07, 2023	SELL	$7.23 - $10.52 $51,369 - $74,744	-7,105 Reduced 33.26%	14,256 $103,000
Q1 2023 May 09, 2023	SELL	$7.81 - $11.05 $22,969 - $32,498	-2,941 Reduced 12.1%	21,361 $180,000
Q4 2022 Feb 09, 2023	BUY	$6.52 - $8.95 $40,208 - $55,194	6,167 Added 34.01%	24,302 $182,000
Q3 2022 Nov 09, 2022	SELL	$7.76 - $13.72 $90,233 - $159,536	-11,628 Reduced 39.07%	18,135 $145,000
Q2 2022 Aug 10, 2022	BUY	$10.22 - $13.94 $304,177 - $414,896	29,763 New	29,763 $345,000

168

47.8M

130K

51K

Ticker EOLS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 56,094,800
Market Cap $609M
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.